1. Home
  2. EHGO vs GNLX Comparison

EHGO vs GNLX Comparison

Compare EHGO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EHGO
  • GNLX
  • Stock Information
  • Founded
  • EHGO 2015
  • GNLX 2001
  • Country
  • EHGO China
  • GNLX United States
  • Employees
  • EHGO N/A
  • GNLX N/A
  • Industry
  • EHGO
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EHGO
  • GNLX Health Care
  • Exchange
  • EHGO NYSE
  • GNLX Nasdaq
  • Market Cap
  • EHGO 28.3M
  • GNLX 184.4M
  • IPO Year
  • EHGO 2024
  • GNLX 2023
  • Fundamental
  • Price
  • EHGO $1.07
  • GNLX $3.58
  • Analyst Decision
  • EHGO
  • GNLX Strong Buy
  • Analyst Count
  • EHGO 0
  • GNLX 4
  • Target Price
  • EHGO N/A
  • GNLX $18.25
  • AVG Volume (30 Days)
  • EHGO 45.6K
  • GNLX 174.5K
  • Earning Date
  • EHGO 03-21-2025
  • GNLX 03-31-2025
  • Dividend Yield
  • EHGO N/A
  • GNLX N/A
  • EPS Growth
  • EHGO N/A
  • GNLX N/A
  • EPS
  • EHGO 0.00
  • GNLX N/A
  • Revenue
  • EHGO $16,963,957.00
  • GNLX $8,000.00
  • Revenue This Year
  • EHGO N/A
  • GNLX N/A
  • Revenue Next Year
  • EHGO N/A
  • GNLX N/A
  • P/E Ratio
  • EHGO $3,149.40
  • GNLX N/A
  • Revenue Growth
  • EHGO N/A
  • GNLX N/A
  • 52 Week Low
  • EHGO $0.91
  • GNLX $1.60
  • 52 Week High
  • EHGO $5.50
  • GNLX $7.04
  • Technical
  • Relative Strength Index (RSI)
  • EHGO N/A
  • GNLX 42.56
  • Support Level
  • EHGO N/A
  • GNLX $3.51
  • Resistance Level
  • EHGO N/A
  • GNLX $4.37
  • Average True Range (ATR)
  • EHGO 0.00
  • GNLX 0.44
  • MACD
  • EHGO 0.00
  • GNLX -0.13
  • Stochastic Oscillator
  • EHGO 0.00
  • GNLX 12.82

About EHGO ESHALLGO INC

Eshallgo Inc. focuses on two distinct market sectors: office supply sale and leasing, and after-sale maintenance and repair. It is an authorized distributor of brands of office equipment, including HP, Epson, Xerox, Sharp, Toshiba, Konica, Kyocera, and other brands.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Share on Social Networks: